Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EPS (Basic): 2016-2024

Historic EPS (Basic) for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to -$0.33.

  • Akebia Therapeutics' EPS (Basic) rose 102.04% to $0.00 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.08, marking a year-over-year increase of 66.03%. This contributed to the annual value of -$0.33 for FY2024, which is 17.86% down from last year.
  • Akebia Therapeutics' EPS (Basic) amounted to -$0.33 in FY2024, which was down 17.86% from -$0.28 recorded in FY2023.
  • Over the past 5 years, Akebia Therapeutics' EPS (Basic) peaked at -$0.28 during FY2023, and registered a low of -$2.78 during FY2020.
  • Over the past 3 years, Akebia Therapeutics' median EPS (Basic) value was -$0.33 (recorded in 2024), while the average stood at -$0.38.
  • Per our database at Business Quant, Akebia Therapeutics' EPS (Basic) soared by 69.41% in 2022 and then decreased by 17.86% in 2024.
  • Over the past 5 years, Akebia Therapeutics' EPS (Basic) (Yearly) stood at -$2.78 in 2020, then spiked by 38.85% to -$1.70 in 2021, then soared by 69.41% to -$0.52 in 2022, then surged by 46.15% to -$0.28 in 2023, then declined by 17.86% to -$0.33 in 2024.